Phase II trial of Cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study.

Authors
Rembielak, Agata
Jain, Pooja
Jackson, Andrew
Green, Matthew M L
Santorelli, Gillian R
Whitfield, Gillian A
Crellin, A
Garcia-Alonso, A
Radhakrishna, G
Cullen, James N
Taylor, Benjamin
Swindell, Ric
West, Catharine M L
Valle, Juan W
Saleem, Azeem
Price, Patricia M
Affiliation
Academic Department of Radiation Oncology, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Issue Date
2014-02

Metadata
Show full item record
Abstract
Preclinical data have indicated the anti-epidermal growth factor receptor (EGFR) agent cetuximab (Erbitux) as a radiosensitizer in pancreatic cancer, but this has not been specifically addressed in a clinical study. We report the results of an original study initiated in 2007, where cetuximab was tested with radiotherapy (RT) alone in locally advanced pancreatic cancer in a phase II trial (PACER).
Citation
Phase II trial of Cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study. 2014, 7 (1):55-64 Transl Oncol
Journal
Translational Oncology
URI
http://hdl.handle.net/10541/320673
PubMed ID
24772208
Type
Article
Language
en
ISSN
1936-5233
Collections